The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]
Todd Feaster, PsyD
Advertisement
Senior clinical research scientist at Acumen Pharmaceuticals.
Articles by Todd Feaster, PsyD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
NRLP3 Inhibitor VTX3232 Well-Tolerated, Improves Parkinson Symptoms in Phase 2a Trial
2
Exploring the Role of Aerobic Exercise in Promoting Remyelination in Multiple Sclerosis: Lindsey Wooliscroft, MD, MS
3
Interim ROSSINI Data Highlight Foslevodopa/Foscarbidopa’s Impact in Advanced Parkinson Disease
4
Unmet Needs in Myasthenia Gravis Care
5
